Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2016 3
2018 1
2019 1
2020 4
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Update on glioma biotechnology.
Abrams M, Reichman N, Khatri D, Patel NV, D'Amico RS, Wong T, Fralin S, Li M, Symons M, Langer D, Filippi CG, Boockvar JA. Abrams M, et al. Among authors: fralin s. Clin Neurol Neurosurg. 2020 Aug;195:106075. doi: 10.1016/j.clineuro.2020.106075. Epub 2020 Jul 7. Clin Neurol Neurosurg. 2020. PMID: 32653731 Review.
Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial.
Patel NV, Wong T, Fralin SR, Li M, McKeown A, Gruber D, D'Amico RS, Patsalides A, Tsiouris A, Stefanov DG, Flores O, Zlochower A, Filippi CG, Ortiz R, Langer DJ, Boockvar JA. Patel NV, et al. Among authors: fralin sr. J Neurooncol. 2021 Nov;155(2):117-124. doi: 10.1007/s11060-021-03851-2. Epub 2021 Oct 3. J Neurooncol. 2021. PMID: 34601657 Clinical Trial.
Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.
Boockvar JA, Tsiouris AJ, Hofstetter CP, Kovanlikaya I, Fralin S, Kesavabhotla K, Seedial SM, Pannullo SC, Schwartz TH, Stieg P, Zimmerman RD, Knopman J, Scheff RJ, Christos P, Vallabhajosula S, Riina HA. Boockvar JA, et al. Among authors: fralin s. J Neurosurg. 2011 Mar;114(3):624-32. doi: 10.3171/2010.9.JNS101223. Epub 2010 Oct 22. J Neurosurg. 2011. PMID: 20964595 Free PMC article. Clinical Trial.
Erratum to: Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.
Chakraborty S, Filippi CG, Wong T, Ray A, Fralin S, Tsiouris AJ, Praminick B, Demopoulos A, McCrea HJ, Bodhinayake I, Ortiz R, Langer DJ, Boockvar JA. Chakraborty S, et al. Among authors: fralin s. J Neurooncol. 2016 Jul;128(3):417. doi: 10.1007/s11060-016-2153-6. J Neurooncol. 2016. PMID: 27270719 No abstract available.
Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.
Chakraborty S, Filippi CG, Wong T, Ray A, Fralin S, Tsiouris AJ, Praminick B, Demopoulos A, McCrea HJ, Bodhinayake I, Ortiz R, Langer DJ, Boockvar JA. Chakraborty S, et al. Among authors: fralin s. J Neurooncol. 2016 Jul;128(3):405-15. doi: 10.1007/s11060-016-2099-8. Epub 2016 Mar 5. J Neurooncol. 2016. PMID: 26945581 Clinical Trial.
12 results